Forecasting disease progression

About us

We are an AI-driven precision medicine company developing a multimodal prognostic platform to forecast disease progression in age-related disorders. Our forecasts provide new tools to physicians for improved patient care and to pharmaceutical companies for faster drug development. Our current applications are in Alzheimer's disease.

Foresight™ - Our Predictive Platform

Multimodal

Our platform can leverage multiple sources of data (imaging, genetic, phenotypic, molecular and clinical variables) to better characterize individuals.

High precision targeting

We are able to rapidly and precisely target subgroups of interest in large, heterogeneous populations.

Highly actionable insights

Our digital biomarkers are highly specific and thoroughly validated, making them ready for action in any clinical setting.

To learn more, visit our Publications page!

Latest News

Perceiv AI announces an investment of $1.5M from strategic and institutional investors to support the expansion of its prognostic platform Foresight(TM).

December 8, 2022 | Montréal, Canada | Press release

Perceiv AI today announced the closing of an investment of $1.5M. Perceiv AI is a precision medicine company optimizing and de-risking clinical trials and enabling physicians to make a timely diagnosis of degenerative brain disorders by forecasting disease evolution.

The round was composed of strategic and institutional investors from Canada and the US, including CABHI (Centre for Aging + Brain Health Innovation), Plug and Play Ventures, Boreal Ventures, IKJ Capital, Red Abbey Labs, Investissement Québec, as a representative of the government of Quebec, as well as angel investors. "We are very excited to move forward to the next phase of our growth with the support of these strategically important investors," said Dr. Christian Dansereau, CEO of Perceiv AI.

The funds will be used to expand the Foresight platform, Perceiv AI's proprietary AI/ML-driven prognostic platform that predicts disease progression. The company aims to add other key resources by bringing additional talent to the team to advance its commercial and scientific activities and strengthen its regulatory effort.

Perceiv AI to present its latest results on mitigating loss of statistical power due to outcome imbalance in clinical trials

November 24, 2022 | Montreal, Canada | Announcement

Join Perceiv AI's senior scientist Angela Tam at our poster #LP005 "Mitigating loss of statistical power due to outcome imbalance in clinical trials" on Tuesday November 29 to Wednesday November 30 at Clinical Trials on Alzheimer's Disease (CTAD) 2022. Our team is excited to meet you in San Francisco, California next week.

Oral presentation at Alzheimer's Association International Conference (AAIC 2022)

July 18, 2022 | Montreal, Canada

Join Senior Scientist Dr. Angela Tam as she will give a talk on Perceiv AI’s latest work and performance gain for trial optimization and patients selection at the 2022 Alzheimer's Association International Conference (AAIC 2022) in the Novel Clinical Trial Designs and Outcome Measures session. Dr. Tam’s oral presentation will take place on August 2nd at 9:55am PT at the San Diego Convention Center. More info at: https://aaic.alz.org

Find all our past news and announcements in our Newsroom!

Meet our Team

Christian Dansereau, Ph.D.

CEO & Founder

EmailTwitterLinkedIn

César Laurent, Ph.D.

CTO & Founder

LinkedIn

Angela Tam, Ph.D.

Senior Scientist

LinkedIn

Adrián Noriega de la Colina, M.D., Ph.D.

Clinical and Regulatory Lead

TwitterLinkedIn

Meet our Advisors

Yoshua Bengio

Yoshua Bengio, Ph.D.

Full Professor at Université de Montréal,

Founder and Scientific Director of Mila,

Scientific Director of IVADO

Link
Serge Gauthier

Serge Gauthier, M.D.

Full Professor at McGill University,

Director of the Alzheimer Disease and Related Disorders Research Unit, Douglas Research Centre

Link
Betsabeh Madani Hermann

Betsabeh Madani Hermann, M.B.A.

Healthcare executive & investor,

VP strategy and BD at Philips


LinkedIn

Partners & Collaborators

Mila - Quebec AI Institute
vTv Therapeutics Inc.
Acasti Pharma Inc.
DalCor Pharmaceuticals
Montreal Heart Institute - Institut de Cardiologie de Montréal
CCNA - Canadian Consortium on Neurodegeneration in Aging
CHUM - Centre hospitalier de l'Université de Montréal
Douglas Mental Health University Institute
McGill University

Supported by

CQDM - Consortium de recherche biopharmaceutique
CLSI - California Life Sciences Institute
CTA - Canadian Technology Accelerators
ITEA 4
Montréal Invivo
NVIDIA
Centech
District 3 Innovation Hub
CTS - Campus des Technologies de la Santé